Key result
Ginsenoside Rg5 selectively modulates PPARγ via a novel allosteric pocket to promote beige adipocyte differentiation.
Why the study?
Full agonists of PPARγ such as thiazolidinediones have side effects, motivating the search for selective partial agonists targeting alternative binding pockets for safer therapies.
Structure-based virtual screening identified ginsenoside Rg5 as a novel selective PPARγ modulator that promotes beige adipogenesis, highlighting a potential pathway for safer antidiabetic therapies.
Peroxisome proliferator-activated receptor gamma (PPARγ) is a key target for metabolic disorders that contribute to obesity and type 2 diabetes mellitus (T2DM). However, full agonists such as thiazolidinediones (TZDs) have limitations in terms of side effects. Selective PPARγ modulators (SPPARγMs) that target alternative binding pockets offer the potential for safer partial agonists. Here, we employed six computational algorithms (Fpocket, DeepSite, CavityPlus, DoGSiteScorer, CASTpFold, POCASA) to identify a novel allosteric pocket (pocket 6–5) in the PPARγ ligand-binding domain (LBD), localized at the helix 3 (H3), helix 2 (H2), helix 2'(H2′), and β-sheet interface. A virtual screening of 4,097 natural compounds from traditional Chinese medicine (TCM) libraries was conducted, which led to the identification of ginsenoside Rg5 (TWSZ-5) as a top hit. Molecular docking and molecular dynamics (MD) dynamics revealed TWSZ-5 stabilizes pocket 6–5 through hydrogen bonds with Ser342, Gln345, Lys261, and Lys263. TWSZ-5 promoted beige adipocyte differentiation in adipose-derived stem cells (ADSCs) in vitro, upregulating Ucp1, Prdm16, Cpt1α, and Pgc1α. The present study identifies TWSZ-5 as a novel SPPARγM that utilizes an allosteric binding pocket to enhance thermogenesis while mitigating adverse effects. These findings emphasize the potential of TCM derivatives and structure-based screening strategies to develop safer antidiabetic therapies with precision pharmacology.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied Metabolic disorders (obesity and type 2 diabetes mellitus). Ginsenoside Rg5 (TWSZ-5) vs. Rosiglitazone (RSG) or control was evaluated on Binding affinity, transcriptional activity of PPARγ, and beige adipocyte differentiation. Ginsenoside Rg5 (TWSZ-5) was identified as a novel selective PPARγ modulator that binds to an allosteric pocket (pocket 6-5) to promote beige adipocyte differentiation and upregulate thermogenic genes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: